Objective: To assess the bronchodilator efficacy, safety and tolerability of indacaterol, a
novel, once-daily inhaled β2-agonist bronchodilator, in patients with chronic obstructive …

The presence of acute reversibility to bronchodilators does not distinguish asthma from
COPD. Patients with either condition can benefit from bronchodilators, and should be given …

Asthma is a worldwide chronic disorder that is characterised by airway inflammation and
hyper-responsiveness, which results in intermittent airflow obstruction and subsequent …

Long-acting β 2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in
the treatments of chronic obstructive lung diseases. Although no specific indications …

An increasing body of evidence suggests that the long-acting muscarinic antagonist
(LAMA)/long-acting β2-agonist (LABA) combination appears to play an important role in …

Current asthma treatment recommendations are based on clinical trials demonstrating
improved clinical outcomes of combination ICS plus LABA over ICS alone. Whether LABA …

The addition of an inhaled long-acting β2-agonist (LABA) to an inhaled corticosteroid (ICS)
gives optimal control of asthma in most patients and two fixed combination inhalers …

Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting
muscarinic antagonist [LAMA] plus a long-acting β2-agonist [LABA]) are available for the …

Current guidelines recommend adding a long-acting inhaled β2-agonist (LABA) to inhaled
corticosteroids (ICS) in patients with uncontrolled asthma. This study evaluated the novel …

The introduction of long-acting b-agonist (LABA) drugs in the 1990s was considered a major
advance in bronchodilator therapy with evidence that their use led to improved lung function …